Sarepta疗法 SRPT 深 沪
交易中 01-28 11:02:01 美东时间
21.48
-0.690
-3.11%
华盛通- 最 高22.14
- 今 开22.14
- 成交量 54.16万股
- 最 低 21.335
- 昨 收 22.17
- 总市值 20.99亿
- 52周最高 114.4122
- 市盈率 静 9.19
- 换手率 0.55%
- 52周最低 10.415
- 委 比 10.27%
- 总股本 9771.34万
- 历史最高 181.83
- 量 比 0.74
- 振 幅 3.63%
- 历史最低 0.433
- 每 手 1
- 风险率 31.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings Jan 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMETEK, Stryker and Zimmer Biomet Holdings, on Tuesday. HIGHLIGHTS * AMETEK AME.N : Oppenheimer cuts to
01-27 15:49
Sarepta Says Elevidys Slows Duchenne Progression After Three Years
Sarepta's Elevidys shows significant improvement in motor function measures after three years of treatment, with no new safety signals.
01-26 22:26
UPDATE 1-Sarepta's Duchenne gene therapy slows disease progression, three-year data shows
UPDATE 1-Sarepta's Duchenne gene therapy slows disease progression, three-year data shows Adds shares in paragraph 2, details throughout Jan 26 (Reuters) - Sarepta Therapeutics' SRPT.O gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and
01-26 21:24
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows Jan 26 (Reuters) - Sarepta Therapeutics' SRPT.O gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data f
01-26 21:07
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
Sarepta jumps on upcoming release of 3-year Elevidys data
Sarepta Therapeutics (SRPT) is up ~10% in after-hours trading Friday after announcing it will release topline, 3-year results from its EMBARK study of Elevidys (delandistrogene moxeparvovec) in Duchen...
01-24 06:55
BRIEF-Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy
BRIEF-Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy Jan 23 (Reuters) - Sarepta Therapeutics Inc SRPT.O : SAREPTA THERAPEUTICS TO REPORT 3-YEAR TOPLINE DATA FROM EMBARK STUDY OF ELEVIDYS GENE THERAPY IN AMBULATORY INDIVIDUALS WITH DUCHENNE MUSCULAR DYST
01-24 05:43
Wedbush Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $34
Wedbush analyst Yun Zhong maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $32 to $34.
01-23 22:00
美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
Sarepta guides Q4 sales below estimates
Sarepta Therapeutics (SRPT) estimates total net product revenue of $369.6M ($380.61M estimated) for Q4 and $1.86B ($2.12B estimated) for full-year 2025. Elevidys (delandistrogene moxeparvovec), the fi...
01-13 01:42
